Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The ...

Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial results ...

with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of ...

Neuraxpharm and partner Minoryx Therapeutics, meanwhile, were unable to convince the CHMP that they should get conditional approval for PPAR gamma agonist Nezglyal (leriglitazone) as a treatment ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

The CHMP’s positive opinion of TAK-003 was supported by results across five phase 1, 2, and 3 trials, including four and a half years of follow-up data from the global, pivotal phase 3 ...

and in the first European countries for second-line ESCC and first- and second-line non-small cell lung cancer (NSCLC); ...

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November ...

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...

PTC Therapeutics Inc (PTCT) reports strong Q3 revenue and raises 2024 guidance, while navigating regulatory hurdles and ...

The process is near completion with the CHMP opinion expected next month. As we look forward to achieving marketing approval in the US, we plan to file BLA for KOSTAIVE in the first half of next year ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...